Synergy Pharmaceuticals (SGYP -2.2%) slips after saying it has completed a Phase I clinical...
Friday, December 28, 2012, 1:33 PM ETSynergy Pharmaceuticals (SGYP -2.2%) slips after saying it has completed a Phase I clinical trials of SP-333, a treatment for ulcerative colitis and other GI diseases. According to the results, SP-333 exhibited potent anti-inflammatory activity in animal studies, which the company believes can provide a new way to treat UC patients with mild to moderate disease. The company plans to start a multi-dose escalation trial in January.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles